Nicotinamide → (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

Participants

Role	Name	HCID	Charge
Reactant	Nicotinamide	HCID 936	—
Reactant	Isobutyraldehyde trimethylsilyl enol ether	HCID 99685	—
Reactant	Retinoic Acid	HCID 444795	—
Reactant	Dapt	HCID 5311272	—
Reactant	N-[2-[(3'R,7'aR)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide	HCID 16760383	—
Reactant	CID 49862879	HCID 49862879	—
Product	(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal	HCID 107526	—

Reaction Steps

Cells were reprogrammed according to Example 11, and were then cultured in DMEM/F12, 100 ng/ml activin A, 25 ng/ml Wnt3a, 0.01% recombinant HSA, 1×ITSE for 1 day, followed by DMEM/F12, 100 ng/ml activin A, 0.01% recombinant HSA, 1×ITSE for 2 days, followed by DMEM/F12, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine, 0.01% recombinant HSA, 1×ITSE for 3 days, followed by DMEM/F12, 1% B27, 2 μM all-trans retinoic acid, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine for 4 days, followed by DMEM/F12, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 10 nM betacellulin, 10 mM nicotinamide for 2 days, followed by DMEM/F12, 50 mg/L ascorbic-acid-2-phosphate, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 50 ng/ml IGF-1, 50 ng/ml HGF, 10 nM betacellulin, 10 mM nicotinamide for 6 days to generate glucose-responsive insulin-producing cells (FIG. 5A). The resulting cells can be used in vitro or in vivo for screening bioactive molecules for the study of diabetes or for the development of therapeutics for diabetes.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US09422577B2
Source dataset	uspto-grants-2016_08
ORD ID	ord-b37f66fc11ba448e86674f1bc8ce2d4a
Source note	uspto-grants-2016_08